Metoprolol Succinate
Basic information
- CAS
98418-47-4- Standard SMILES
COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O- InChIKey
RGHAZVBIOOEVQX-UHFFFAOYSA-N- Molecular formula
- C34H56N2O10
- Average molar mass
- 652.8 g/mol
- Monoisotopic mass
- 652.39349599
Overview
Metoprolol succinate is an alcohol and a member of phenols.
Names & identifiers
- Preferred name
- Metoprolol Succinate
- IUPAC
- butanedioic acid;bis(1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol)
- English name
- Metroprolol succinate
- Molecular formula
- 2C15H25NO3.C4H6O4
- Molecular weight
- 652.82
Names & synonyms
Metoprolol succinate98418-47-4SelozokToprol XLSeloken-ZOKMetoprolol hemisuccinateH 93/26 succinateTOPROL-XLDTXSID9048726TH25PD4CCBDTXCID6028652KAPSPARGO
Show more names
rolol succinateMaetaprolol succinateMETOPROLOL SUCCINATE USPMetoprolol succinate BaseMetoprolol Succinate (200 mg)Metoprolol Succinate (ToprolX)
Metoprolol Succinate ERRefChem:55626KAPSPARGO SPRINKLEMetoprolol Succinate E/rMetoprolol Succinate ER TabletsMetoprolol Succinate Extended-releaseToprolMetroprolol succinate
Database identifiers
- CAS
98418-47-4- PubChem CID
- 62937
- DTXSID
DTXSID9048726- ChEMBL
CHEMBL2356097- ChEBI
CHEBI:6905- UNII
- TH25PD4CCB
- EC Number
- 620-476-9
Properties
Computed structural properties
- Topological polar surface area
- 176 Ų
- Hydrogen bond donors
- 6
- Hydrogen bond acceptors
- 12
- Rotatable bonds
- 21
- Heavy atoms
- 46
- Formal charge
- 0
- Complexity
- 308
Experimental & physicochemical properties
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- Melting point
- 136 · 136-138°C
- storage temp.
- Hygroscopic, Refrigerator, under inert atmosphere
- solubility
- Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent), very slightly soluble in ethyl acetate.
- form
- Solid
- color
- White to Off-White
- Stability
- Hygroscopic
- InChI
- InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
- InChIKey
- RGHAZVBIOOEVQX-UHFFFAOYSA-N
- SMILES
- C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1
- FDA UNII
- 25 PD4CCB · TH25PD4CCB
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Danger
H302 (11.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P270, P273, P301+P317, P308+P316, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 52 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Hazard Classes and CategoriesAcute Tox. 4 (11.5%)
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Metoprolol succinate
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Safety data
- hs_code
- 2922190900
- Signal word
- Danger
- Symbol(GHS)
- GHS08
- Hazard statements
- H370
- Precautionary statements
- P308+P311
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
METOPROLOL SUCCINATE
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
METOPROLOL SUCCINATE ER
beta-Adrenergic Blocker [EPC]; Adrenergic beta-Antagonists [MoA]
METOPROLOL SUCCINATE ER TABLETS
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
Applications
DescriptionMetoprolol succinate represents an entirely novel extended-release formulation of metoprolol, requiring administration only once daily to ensure constant metoprolol blood concentrations and sustained β1-adrenergic blocking effects throughout the 24-hour period. It offers numerous advantages in both pharmacology and clinical therapeutics. Clinically, it is primarily indicated for the management of hypertension,High blood pressure medication,angina pectoris, and stable chronic heart failure with left ventricular systolic dysfunction.Administer orally once daily, preferably in the morning. Tablets may be divided but must not be chewed or crushed. Swallow with at least half a glass of liquid. Concomitant food intake does not affect bioavailability. Dosage should be individualised to avoid bradycardia. Effective dosing guidelines are as follows: Hypertension: 47.5–95 mg once daily. Patients unresponsive to 95 mg metoprolol succinate sustained-release tablets may combine with other antihypertensives, preferably diuretics and dihydropyridine calcium channel blockers, or increase dosage. Angina pectoris: 95–190 mg once daily. May be combined with nitrates or increased dosage as required.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…